financetom
Business
financetom
/
Business
/
FS Bancorp Q3 net income falls 11% 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FS Bancorp Q3 net income falls 11% 
Oct 21, 2025 1:55 PM

Overview

* FS Bancorp ( FSBW ) Q3 net income falls to $9.2 mln from $10.3 mln a year ago

* Total deposits rose 5.2% qtr/qtr to $2.69 bln, driven by brokered CDs

* Company repurchased 134,413 shares at $41.15 each in Q3 2025

Outlook

* FS Bancorp ( FSBW ) did not provide specific financial guidance for future quarters in the press release

Result Drivers

* NET INTEREST MARGIN - Co maintained strong net interest margins through higher yields on earning assets

* DEPOSIT GROWTH - Total deposits rose 5.2% qtr/qtr to $2.69 bln, driven by an increase in brokered CDs

* BORROWINGS REDUCTION - Borrowings decreased 44.8% qtr/qtr, aiding interest expense management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $1.18

Q3 Net $9.20

Income mln

Q3 Net $33.70

Interest mln

Income

Q3 $0.28

Dividend

Q3 Net 4.37%

Interest

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for FS Bancorp Inc ( FSBW ) is $45.50, about 14.7% above its October 20 closing price of $38.79

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court
Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court
Mar 5, 2025
11:28 AM EST, 03/05/2025 (MT Newswires) -- Pfizer ( PFE ) and its partner BioNTech (BNTX) have infringed a COVID-19 vaccine patent owned by Moderna ( MRNA ) , Reuters reported Wednesday, citing a German court ruling. The court reportedly ordered Pfizer ( PFE ) and BioNTech to disclose earnings related to the patent's use and pay a compensation to...
Market Chatter: Blackstone Nearing $400 Million Deal to Buy South City Mall in India
Market Chatter: Blackstone Nearing $400 Million Deal to Buy South City Mall in India
Mar 5, 2025
11:29 AM EST, 03/05/2025 (MT Newswires) -- Blackstone (BX) is nearing a transaction to buy South City Mall in Kolkata, India, for $400 million, Bloomberg reported Wednesday, citing unnamed sources with knowledge of the matter. Blackstone is in talks with lenders to line up funding for the deal, the report said. Blackstone didn't immediately respond to MT Newswires' request for...
Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
Mar 5, 2025
11:25 AM EST, 03/05/2025 (MT Newswires) -- Amgen ( AMGN ) has initiated two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference. One of the trials is in people with obesity or overweight without type 2 diabetes, and is expected to enroll 3,500 people, Bradner...
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise
Mar 5, 2025
11:23 AM EST, 03/05/2025 (MT Newswires) -- Pluri ( PLUR ) said Wednesday that it signed an exclusive collaboration deal with Hemafund, an umbilical cord blood bank, for the distribution and clinical advancement of PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome in Ukraine. Pluri ( PLUR ) said it has agreed to produce and supply...
Copyright 2023-2026 - www.financetom.com All Rights Reserved